![]() ![]() Before enrollment, the serum HBV-DNA virus level shall be retested and decreased entecavir), and are willing to continue to receive anti-HBV treatment during the study. Before joining the study, the serum HBV-DNA virus shall be retested and decreased by more than 1 log value ③ For those with HBV DNA > 500 IU / ml and who have received antiviral treatment, they shall receive anti-HBV treatment for at least 7 days before enrollment (according to local treatment standards e.g. Patients with active HBV infection can be enrolled if meeting one of the following conditions: ① within 28 days before enrollment, the patient's HBV DNA is 500 IU / ml and without antiviral treatment, they shall receive anti-HBV treatment for at least 7 days before joining the study (according to local treatment standards e.g.HCC patients treated with TACE can be enrolled only if tumor progression after TACE or 3 months after TACE.Planned to receive one of the following treatment regimen: Atezolizumab and Bevacizumab, Camrelizumab and Apatinib, Sintilimab and Bevacizumab. ![]()
0 Comments
Leave a Reply. |